Yuliang Feng

Yuliang Feng is an Associate Professor and doctoral supervisor in the Department of Pharmacology, School of Medicine, Southern University of Science and Technology (SUSTech), China. He also serves as Vice-Chair of the Pan-Vascular Committee of the Guangdong Medical Education Association and holds editorial/reviewer roles for more than 25 international journals.

Education

• Ph.D. in Molecular & Cellular Medicine, University of Oxford, UK (2019-2022)
• M.D. in Cardiovascular Pharmacology, Joint Ph.D. program, Southern Medical University & University of Cincinnati (2008-2014)
• B.M. in Preventive Medicine, Sun Yat-sen University, China (2003-2008)

Research Interests

Dr. Feng integrates 3-D genomics, epigenomics and computational biology to decode how higher-order chromatin organization governs transcriptional programs in human disease, with a focus on cardiovascular disease and cancer. His laboratory maps enhancer–promoter interactions using Hi-C, ChIA-PET and HiChIP, and develops multi-omics databases (e.g., EXPRESSO) to uncover therapeutic targets that reprogram pathological gene networks.

Recent work reveals shared genetic architectures among major cardiovascular diseases, telomere-length contributions to disease onset, BRD9–SMAD2/3-mediated stemness in pancreatic cancer, and 3-D chromatin rewiring during dilated cardiomyopathy. These studies highlight his expertise in translating genome topology findings into diagnostic and precision-medicine strategies.

Scientific Awards & Honors

• National Science Foundation of China Distinguished Young Scholar (Overseas), 2023
• Guangdong Distinguished Young Scholar, 2023
• Shenzhen Pengcheng Peacock Talent (Category C), 2023
• Clarendon Scholar, University of Oxford, 2019-2022
• ISHR Richard J. Bing Young Investigator Award Finalist, 2022
• Multiple ISHR Young Investigator & Travel Awards (2010-2016)

Grants & Leadership

Dr. Feng currently leads projects funded by the National Natural Science Foundation of China and Guangdong Province, and participates in international consortia such as ENCODE, 4DN and BLUEPRINT. He mentors graduate students and postdocs, while coordinating collaborative teams across SUSTech, Oxford, and industry partners to develop next-generation epigenomic therapeutics.

Laboratory & Teams

The Feng lab operates within the SUSTech Medical Research Platform with access to state-of-the-art sequencing, single-cell and high-performance computing cores. The group maintains active collaborations with cardiac surgeons, oncologists and AI scientists to accelerate bench-to-bedside translation of 3-D genome-based interventions.